Laresin

Olmesartan medoxomil, the active ingredient in Laresin, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension. By selectively blocking AT1 receptors, it prevents vasoconstriction and aldosterone‑mediated fluid retention, contributing to sustained blood‑pressure control.

GNH USA supplies Laresin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under GMP conditions.

Olmesartan medoxomil is used to treat conditions related to the renin‑angiotensin system, primarily hypertension.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications such as stroke and myocardial infarction.

Common side effects are generally mild and may resolve without intervention.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Abdominal discomfort - Diarrhea - Nasal congestion

Serious or Rare Side Effects: - Hyperkalemia (elevated blood potassium) - Acute kidney injury - Angioedema (swelling of face, lips, tongue) - Severe hypotension - Hepatic enzyme elevation - Allergic skin reactions such as rash or pruritus

Olmesartan medoxomil should be used with caution in specific clinical situations. - Renal impairment: monitor kidney function and serum electrolytes regularly. - Hyperkalemia risk: avoid concomitant potassium‑rich supplements or potassium‑sparing diuretics. - Pregnancy: discontinue if pregnancy is confirmed; safety category is unknown. - Elderly patients: start at lower doses and titrate slowly. - Drug interactions: review all concomitant medications for potential additive effects. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in the original packaging.

Olmesartan medoxomil can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: increased risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: combined use can lead to excessive blood‑pressure reduction and renal impairment.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish antihypertensive effect and affect renal function. - Lithium: can increase lithium levels, risking toxicity. - Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustments to avoid hypotension.